



## Clinical Update

### Changes on Interpretative Comments as of 20 December 2018

Illumiscreen is a high quality non-invasive prenatal screening (NIPS) service with IANZ accreditation. Participation in External Quality Assurance Programs (EQAPs) is part of our quality framework and we have enrolled in the EQAPs of the European Molecular Quality Network and the College of American Pathologists. These programmes have recommended using the terms “high risk/ low risk” for the interpretative comments in the NIPS reports, which are also more clinically oriented. This will replace the more technical descriptions currently in our reports. For the results, the categorisation remains the same as “No Aneuploidy Detected”, “Aneuploidy Detected” and “Aneuploidy Suspected [Borderline Result]”.

Using chromosome 21 as an example, the interpretative comment for no aneuploidy detected would become “Result indicates low risk for trisomy 21 (Down Syndrome)”. For aneuploidy detected, the interpretative comment would be “Result indicates high risk for trisomy 21 (Down Syndrome)”.

The changes involved are only the wordings in the reports. All the other aspects of the test remain the same.